^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access

Published date:
11/04/2020
Excerpt:
Interestingly, the child with KMT2A-rearranged infant AML achieved a molecular CR after salvage therapy with Vyxeos plus crenolanib. This child was successfully bridged to a second HSCT and remains in remission one year after the start of his compassionate use crenolanib....FLT3 status....FLT3 A848P....co-occuring mutations....KMT2A-MLLT3....CR with full count recovery, MRD negative, PET negative, achieved CR, haplo HSCT in 9mths ago, In continued remission of all treatment.
DOI:
https://doi.org/10.1182/blood-2020-140399